Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Inovio Biomedical's partner, Tripep has reported preliminary results from the first patient to complete treatment with Tripep's therapeutic hepatitis C virus vaccine, ChronVac-C, which was delivered using Inovio's electroporation-based DNA delivery system.
Subscribe to our email newsletter
In this Phase I/II clinical study, the treatment has so far been safe and tolerable. Samples taken before, during and after treatment showed that before vaccination the patient did not have a detectable cell-mediated immune response against hepatitis C virus (HCV) but such an immune response became detectable after treatment was completed. Inovio’s electroporation delivery technology is intended to enhance the potency of DNA-based immunotherapies, including DNA vaccines, against cancers and infectious diseases.
Avtar Dhillon, Inovio’s president and CEO, said: “We look forward to seeing additional data, particularly from the higher dose groups, relating to this potential treatment to a pervasive and difficult-to-treat disease.”